PharmAust Pharmaceutical Information

View Top Employees from PharmAust Pharmaceutical

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for humans and animals. The company develops drugs for the treatment of various cancers, and viral and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug for the treatment of cancer. PharmAust has completed Phase 1 clinical trials with monepantel in human and dog diagnosed with solid tumors, as well as initiated a Phase 2 pilot study in dogs diagnosed with Lymphoma. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Website	http://pharmaust.com
Ticker	PAA
Revenue	$2 million
Employees	View employees
Founded	2003
Address	5/3 Brodie Hall Dr, Bentley, Western Australia 6102, AU
Phone	+61 8 9202 6814
Fax	+61 8 9467 6111
Technologies	JavaScript , HTML , PHP +17 more (view full list)
Industry	Pharmaceutical Manufacturing, Manufacturing General, Drug Discovery, Manufacturing, Other Pharmaceuticals and Biotechnology
Competitors	Sage Therapeutics, Acorda Therapeutics, Inc., Seres Therapeutics, Vaxart, Inc., Galectin Therapeutics, OncoSec, Zynerba Pharmaceuticals, Ampio Pharmaceuticals, Inc., Aptinyx Inc., Paragon Pharmaceuticals +35 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 283 Companies
NAICS	NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies